We report a case of a 34-year-old man with T-ALL and ␤-thalassaemia major who underwent a one antigen mismatched related donor bone marrow transplant. Five months post transplant chimeric studies revealed full donor haemopoiesis and the patient remains leukaemia and thalassaemia free at 12 months post transplant. Cumulative risk factors contributing to the increased transplant-related mortality in patients with two different marrow disorders are discussed. Bone Marrow Transplantation (2000) 25, 677-678. Keywords: thalassaemia major; acute lymphoblastic leukaemia; bone marrow transplantation Despite remarkable advances in survival rate of children with acute lymphoblastic leukaemia the outcome in adults remains poor with an overall survival rate of approximately 30%. Approaches such as autologous or allogeneic transplantation of haemopoietic progenitors have been adopted in an effort to improve survival rate especially in patients with adverse prognostic factors.
Despite remarkable advances in survival rate of children with acute lymphoblastic leukaemia the outcome in adults remains poor with an overall survival rate of approximately 30%. Approaches such as autologous or allogeneic transplantation of haemopoietic progenitors have been adopted in an effort to improve survival rate especially in patients with adverse prognostic factors.
More recently, bone marrow transplantation has been extended to include disorders other than malignancies such as haemoglobinopathies. BMT in thalassaemia major can eradicate the disease. However, given the high survival rate with red cell transfusion and regular chelation the best approach is still debatable.
Case report
A 34-year-old Cypriot male with transfusion-dependent ␤-thalassaemia was diagnosed as having T-ALL when he presented with a short history of tiredness and night sweats. The presenting white cell count was 150 × 10 9 /l and CNS Correspondence: Dr PD Kottaridis, Clinical Lecturer in Haematology, University College London Hospitals, Department of Haematology 3rd Floor, Grafton Way, London, WC1E 6AU, UK Received 3 August 1999; accepted 7 November 1999 involvement was found on routine LP at the time of diagnosis. Cytogenetics revealed hypodiploidy with complex random translocations. The patient was commenced on the UKALLX protocol (vincristine, prednisolone, asparaginase, etoposide, cytarabine, thioguanine, daunorubicin) and achieved partial remission (PR) on day 30 (blasts 17%) and complete remission (CR) on day 60 (blasts Ͻ5%) of induction treatment. He completed phases I and II of induction and was subsequently referred to our hospital to undergo a one antigen mismatched related donor bone marrow transplant (HLA type of recipient: A1, A28(69), B35, B40(60), DRB1 1601,03011; of donor: A1, A28(69), B35, B27, DRB1 1601,03011). Chelation history and iron studies before the diagnosis of leukaemia, in conjunction with liver biopsy, allowed him to be classified as class 2 according to Pesaro's transplant risk factors 1,2 (regular chelation with ferritin Ͻ1000 g/l prior to leukaemia diagnosis, no hepatomegaly, presence of portal fibrosis). Conditioning consisted of cyclophosphamide 60 mg/kg/day for 2 days and total body irradiation 1440 cGy in eight fractions. Cyclosporin and methotrexate were given for GVHD prophylaxis. The patient was group A Rh positive, CMV seropositive and received unmanipulated marrow from an O Rh positive CMV seropositive 30-year-old male donor, who was also heterozygous for ␤-thalassaemia.
The patient had a smooth initial post-transplant course and apart from severe oral mucositis no major complications occurred. Neutrophil engraftment occurred on day +20 (neutrophils Ͼ0.5 × 10 9 /l) and he became platelet transfusion independent on day +38 (platelets Ͼ20 × 10 9 /l). On day +23 he developed a picture of interstitial pneumonitis but bronchoalveolar lavage (BAL), blood cultures and virological screening failed to isolate any pathogens. He was treated with antimicrobials, antifungals and subsequently with high-dose steroids on the basis of presumed radiation pneumonitis after failing to respond to initial treatment. His clinical status improved substantially over the following 2 weeks. On day +42 he developed grade II skin GVHD which was controlled with topical steroids. During weeks 6 and 7 post transplant the presence of CMV DNA was detected in the blood by PCR surveillance testing (nested PCR method as previously described), 3 and he was therefore commenced on a 2 week course of ganciclovir which rendered him CMV PCR negative. Throughout this period the patient remained entirely asymptomatic. Currently, he remains in remission and independent of red cell transfusions 12 months post transplant, without evidence of GVHD, and off all immunosuppressives. His haemoglobin stabilised at 10 g/dl and he has been commenced on gentle regular venesection in the view of elevated ferritin at 3600 g/l. Microsatellite marker studies confirm full donor chimerism (shown in granulocytes, B and T lymphocytes, see Figure 1 ).
Discussion
Bone marrow transplantation remains the potentially curative treatment for thalassaemia major. However, the dilemma of selecting the best treatment for a patient who may have a substantially improved life expectancy with regular red cell transfusion and chelation, makes the choice for the individual patient very difficult. BMT is an established approach for haematological malignancies and can offer higher rates of disease-free survival for some disorders as compared to conventional chemotherapy. Clinical trials have shown that 65-85% of adult patients with ALL may achieve complete remission with chemotherapy alone. However, these remissions have been disappointedly short. Optimal post-remission therapy remains controversial for adults with ALL in first remission. Some reports have shown a difference favouring transplantation in patients with adverse prognostic factors. 4 Our patient, despite having T-ALL which is considered a subtype with a better prognosis, had a number of these adverse prognostic features (leukocytosis at presentation, CNS involvement, failure to achieve CR on day 30, hypodiploidy). With these features alone and without the thalassaemia a fully matched sibling bone marrow transplant would have offered an event-free survival of approximately 40-50%. 4 Considering only his thalassaemia, a 50-60% overall survival might be predicted for this patient. The Pesaro group 5 has recently updated their experience on adult patients with class 2 or 3 transplant risk status who underwent an HLA-identical sibling allograft for thalassaemia and have reported a 62% probability of 5 year rejection-free survival with 66% overall survival. In our case the projected mortality risk was high considering the two different marrow disorders with cumulative adverse prognostic factors and a graft not perfectly matched from a related donor. However, this approach offered a potential cure for both the inherited and acquired blood disorders.
In summary we report the first case to our knowledge of an allogeneic bone marrow transplant for ALL and thalassaemia major in an adult patient with unfavourable risk factors. This has resulted in full donor haemopoiesis, transfusion independence, leukaemia remission and potential improvement in the quality of life.
